Kathleen M. Madden discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.
Kathleen M. Madden, MSN, FNP-BC, AOCNP
Advertisement
Articles by Kathleen M. Madden, MSN, FNP-BC, AOCNP
Advertisement
Latest Updated Articles
Kathleen Madden on Managing AEs From Targeted Therapies for MelanomaPublished: February 10th 2016 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Monitoring Later Cytopenias With CAR T-Cell Therapy
2
Frontline Vaccine/Pembro Yields PFS Benefit in Advanced Melanoma
3
FDA Approves Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
4
Durvalumab/FLOT Boosts OS in Resectable Gastric Cancer
5
